Takeda Pharmaceutical Co (FRA:TKD) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


FRA:TKD Takeda Pharmaceutical Co Ltd FRA:TKD
67 GF Score
Price €27.26
GF Value €24.44
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Takeda Pharmaceutical Co's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:TKD vs ZTS, UTHR: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Takeda Pharmaceutical Co Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Margin of Safety % (DCF Earnings Based) falls into.


FRA:TKD
67GF Score
Takeda Pharmaceutical Co Ltd FRA:TKD
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Takeda Pharmaceutical Co (FRA:TKD) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of €27.26 is trading 11.5% above its estimated GF Value™ of €24.44. GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for FRA:TKD:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €24.44 vs. price of €27.26 (11.5% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the FRA:TKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
67GF Score

Get the complete analysis for FRA:TKD

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.26
Price
€24.44
GF Value